此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

癌症幸存者计划 (SURV-QoL)

2026年11月2日 更新者:Masaryk Memorial Cancer Institute

癌症幸存者计划:乳腺癌和前列腺癌根治性治疗完成后不良事件监测的有效性

The questionnaire for assessment of adverse events after completion of cancer treatment, which is being piloted at the Masaryk Memorial Cancer Institute, aims to detect a wide range of adverse effects early on, thus facilitating adequate intervention and planning of follow-up care for all cancer survivors.

研究概览

详细说明

According to the current recommendations of the European Society for Medical Oncology (ESMO), comprehensive care for cancer survivors should focus on five main areas: 1) the physical effects of the disease and subsequent treatment, 2) the psychological effects of the disease and treatment, 3) the social, occupational, and financial impacts of the disease and treatment, 4) early detection of recurrence or subsequent primary malignancies, and last but not least, 5) prevention of cancer and promotion of healthy lifestyles.

The proposed questionnaire should effectively and comprehensively reflect both the physical problems typically associated with a given diagnosis and the psychological, social, occupational, and financial impacts. It should also focus the physician's attention on interventions aimed at healthy lifestyles (smoking cessation, obesity prevention, sufficient physical activity) to maintain the health of cancer survivors.

研究类型

介入性

注册 (估计的)

200

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Brno、捷克语、656 53
        • 招聘中
        • Masaryk Memorial Cancer Institute
        • 接触:
        • 接触:
        • 首席研究员:
          • Lenka Pavčíková, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • The patient understands the information provided and agrees to participate in the study.

  • Age 18 years or older.

  • Histologically confirmed invasive breast cancer or invasive prostate cancer.

  • Completion of the acute phase of curative oncological therapy:

    • for breast cancer: curative surgery performed + completed neoadjuvant/adjuvant chemotherapy and completed adjuvant radiotherapy, if indicated
    • for prostate cancer: completed radiotherapy with curative intent or radical prostatectomy performed (open, laparoscopic, robotic) or completed adjuvant radiotherapy after prostatectomy
  • The patient is available for follow-up within 12 months of enrollment in the study.

Exclusion Criteria:

  • Active ongoing oncological therapy (except for (i) adjuvant hormone therapy, (ii) adjuvant targeted therapy (anti-HER2 therapy, CDK4/6i, PARPi, T-DM1), (iii) adjuvant immunotherapy)
  • Neoadjuvant/adjuvant therapy did not include chemotherapy (breast cancer).
  • Recurrence of cancer
  • Metastatic disease
  • History of other primary malignancy (except for non-melanoma skin cancer)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Interventional

screening of adverse effects of curative therapy + quality of life screening

Based on the Questionnaire for the Assessment of Difficulties after the completion of cancer treatment, the attending physician will assess the need for intervention and respond appropriately to the reported problems. Intervention is assessed as education by the physician, the use of medication, or referral of the patient to a specialized outpatient clinic.

无干预:Control

quality of life screening

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Impact of active monitoring of adverse effects on quality of life
大体时间:Upon enrollment (baseline), six and twelve months after baseline

Compare the quality of life of breast and prostate cancer survivors between the interventional group, in which adverse effects are actively monitored using the Questionnaire for the Assessment of Difficulties after Cancer Treatment, and the control group.

Upon enrollment (baseline), six and twelve months after baseline

次要结果测量

结果测量
措施说明
大体时间
Comprehensibility of the questionnaire
大体时间:Upon enrollment (baseline), six and twelve months after baseline

Evaluation of the comprehensibility of the Questionnaire for the Assessment of Difficulties after Cancer Treatment.

Upon enrollment (baseline), six and twelve months after baseline
Usability of the questionnaire in routine clinical practice
大体时间:Upon enrollment (baseline), six and twelve months after baseline

Evaluation of the usability of the Questionnaire for the Assessment of Difficulties in routine clinical practice.

Upon enrollment (baseline), six and twelve months after baseline
Frequency of active intervention by a physician
大体时间:Upon enrollment (baseline), six and twelve months after baseline

Assessment of the impact of active monitoring of adverse effects, based on the Questionnaire for the Assessment of Difficulties after Cancer Treatment, on the frequency of active physician interventions in the interventional group.

Upon enrollment (baseline), six and twelve months after baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年5月5日

初级完成 (实际的)

2026年9月5日

研究完成 (估计的)

2026年12月31日

研究注册日期

首次提交

2025年11月19日

首先提交符合 QC 标准的

2025年11月19日

首次发布 (实际的)

2025年11月28日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

IPD to be shared in pseudonymized form during the study. IPD to be published in anonymized form.

IPD 共享时间框架

after study completion

IPD 共享访问标准

During the study, data will be managed in pseudonymized form in a protected database environment, available only for study team.

After completion of the study, the data will be fully anonymized for publication purposes. All publication outputs of the study will be carried out by a team of researchers led by the principal investigator. The submission of each publication is subject to the approval of the principal investigator.

The results of this study may be published or presented at scientific meetings after approval by the PI and always after anonymization of the subjects' personal data in accordance with Act No. 101/2000 Coll., on the protection of personal data.

IPD 共享支持信息类型

  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅